Development
Traws Pharma, Inc.
TRAW
$1.50
-$0.0208-1.37%
NASDAQ
| 09/30/2023 | 06/30/2023 | 03/31/2023 | 12/31/2022 | 09/30/2022 | |
|---|---|---|---|---|---|
| Revenue | 57.00K | 57.00K | 56.00K | 56.00K | 57.00K |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 57.00K | 57.00K | 56.00K | 56.00K | 57.00K |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | 57.00K | 57.00K | 56.00K | 56.00K | 57.00K |
| SG&A Expenses | 2.69M | 2.21M | 2.11M | 2.02M | 2.11M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 5.15M | 4.67M | 6.19M | 5.79M | 5.70M |
| Operating Income | -5.09M | -4.61M | -6.14M | -5.73M | -5.64M |
| Income Before Tax | -4.74M | -4.25M | -5.78M | -5.42M | -5.40M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -4.74M | -4.25M | -5.78M | -5.42M | -5.40M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -4.74M | -4.25M | -5.78M | -5.42M | -5.40M |
| EBIT | -5.09M | -4.61M | -6.14M | -5.73M | -5.64M |
| EBITDA | -5.08M | -4.61M | -6.13M | -5.73M | -5.64M |
| EPS Basic | -0.23 | -0.20 | -0.28 | -0.26 | -0.26 |
| Normalized Basic EPS | -0.14 | -0.13 | -0.17 | -0.16 | -0.16 |
| EPS Diluted | -0.23 | -0.20 | -0.28 | -0.26 | -0.26 |
| Normalized Diluted EPS | -0.14 | -0.13 | -0.17 | -0.16 | -0.16 |
| Average Basic Shares Outstanding | 21.00M | 20.98M | 20.96M | 20.93M | 20.92M |
| Average Diluted Shares Outstanding | 21.00M | 20.98M | 20.96M | 20.93M | 20.92M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |